$BSX · Boston Scientific Corporation
Boston Scientific Corporation filed a preliminary prospectus supplement dated November 19, 2026, for a proposed offering of four series of senior notes. The specific aggregate principal amounts, interest rates, and maturity dates for each series were left blank in the filing, indicating the terms were not yet finalized. The notes will be senior unsecured obligations, ranking equally with the company’s existing and future unsecured and unsubordinated debt, and will not be listed on any securities exchange.
The company stated it intends to use the net proceeds, together with proceeds from a separate Euro notes offering, short-term borrowings, credit agreement borrowings, and cash on hand, to fund the cash consideration for its agreed acquisition of Penumbra, Inc. and related fees and expenses. Any remaining proceeds may be used for general corporate purposes. The offering is not conditioned on completion of the Penumbra acquisition. However, if the acquisition is not completed by the applicable outside date, initially January 14, 2027 and extendable to January 14, 2028, or Boston Scientific notifies the trustee it will not pursue the deal, the company must redeem the notes at 101% of principal plus accrued interest. The notes also include optional redemption provisions and a change of control repurchase requirement.